Drugs / Mexoryl SX / XL
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | ANTHELIOS SX | — | 2006-07-21 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03582215 | Jul 2018 → Feb 2019 | skin sensitivity to sun | Food and Drug Administration (FDA) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00701740 Comparator | Jul 2007 → Jan 2008 | — | Federal University of São Paulo | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mexoryl SX / XL | “oral isotretinoin and Mexoryl SX / XL” NCT00701740 ↗ |
| Known as | Ecamsule | “Ingredients: 2% Avobenzone; 10% Octocrylene; 2% Ecamsule” NCT03582215 ↗ |